TCRX TScan Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TCRX

Price (delayed)

$1.02

Market cap

$66.66M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.96

Enterprise value

$26.11M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 32
Highlights
The EPS has increased by 12% YoY and by 4% QoQ
TScan Therapeutics's debt has decreased by 4.6% YoY
TScan Therapeutics's revenue has surged by 107% YoY but it has decreased by 12% QoQ
TCRX's gross profit has soared by 107% YoY but it is down by 12% from the previous quarter
The equity has plunged by 54% YoY and by 21% from the previous quarter
TScan Therapeutics's quick ratio has decreased by 23% YoY and by 21% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of TCRX

TCRX stock price

How has the TScan Therapeutics stock price performed over time
Intraday
4.94%
1 week
-5.56%
1 month
-16.39%
1 year
-42.7%
YTD
2%
QTD
0.99%

Financial performance

How have TScan Therapeutics's revenue and profit performed over time
Revenue
$9.14M
Gross profit
$9.14M
Operating income
-$128.7M
Net income
-$124.31M
Gross margin
100%
Net margin
-1,360.6%
TScan Therapeutics's revenue has surged by 107% YoY but it has decreased by 12% QoQ
TCRX's gross profit has soared by 107% YoY but it is down by 12% from the previous quarter
The operating margin has soared by 55% YoY but it has decreased by 7% from the previous quarter
TScan Therapeutics's net margin has surged by 54% YoY but it has decreased by 8% QoQ

Price vs fundamentals

How does TCRX's price correlate with its fundamentals

Growth

What is TScan Therapeutics's growth rate over time

Valuation

What is TScan Therapeutics stock price valuation
P/E
N/A
P/B
0.6
P/S
14.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.86
The EPS has increased by 12% YoY and by 4% QoQ
The equity has plunged by 54% YoY and by 21% from the previous quarter
The price to book (P/B) is 29% lower than the 5-year quarterly average of 0.8 and 5% lower than the last 4 quarters average of 0.6
TScan Therapeutics's revenue has surged by 107% YoY but it has decreased by 12% QoQ
The price to sales (P/S) is 47% lower than the 5-year quarterly average of 26.3 and 33% lower than the last 4 quarters average of 20.5

Efficiency

How efficient is TScan Therapeutics business performance
TScan Therapeutics's ROE has plunged by 64% YoY and by 16% from the previous quarter
The ROS has soared by 54% YoY but it has decreased by 8% QoQ
TScan Therapeutics's ROIC has decreased by 41% YoY and by 11% from the previous quarter
The company's return on assets fell by 36% YoY and by 8% QoQ

Dividends

What is TCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TCRX.

Financial health

How did TScan Therapeutics financials performed over time
The total assets is 92% greater than the total liabilities
The total assets has declined by 39% year-on-year and by 12% since the previous quarter
TScan Therapeutics's quick ratio has decreased by 23% YoY and by 21% QoQ
TScan Therapeutics's debt is 4.5% lower than its equity
The debt to equity has soared by 107% year-on-year and by 25% since the previous quarter
The equity has plunged by 54% YoY and by 21% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.